• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The efficacy and safety of intravitreal dexamethasone implants for macular oedema secondary to retinal vein occlusion: 3-year experience.

作者信息

Higham Aisling, Jacob Sarita, Cox Miriam, Baker Catherine, Al-Husainy Sahar, Sivaraj Ramesh, Gibson Jonathan M

机构信息

Department of Ophthalmology, Heart of England Foundation Trust, Birmingham, West Midlands, UK.

出版信息

Acta Ophthalmol. 2016 Nov;94(7):e674-e675. doi: 10.1111/aos.13021. Epub 2016 Mar 24.

DOI:10.1111/aos.13021
PMID:27010078
Abstract
摘要

相似文献

1
The efficacy and safety of intravitreal dexamethasone implants for macular oedema secondary to retinal vein occlusion: 3-year experience.玻璃体内注射地塞米松植入物治疗视网膜静脉阻塞继发黄斑水肿的疗效与安全性：3年经验
Acta Ophthalmol. 2016 Nov;94(7):e674-e675. doi: 10.1111/aos.13021. Epub 2016 Mar 24.
2
Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.雷珠单抗与地塞米松植入物治疗视网膜分支静脉阻塞继发黄斑水肿的两年疗效
Optom Vis Sci. 2018 Dec;95(12):1149-1154. doi: 10.1097/OPX.0000000000001306.
3
Sequential therapy with ranibizumab and dexamethasone intravitreal implant is better than dexamethasone monotherapy for macular oedema due to retinal vein occlusion.对于视网膜静脉阻塞所致黄斑水肿，雷珠单抗与地塞米松玻璃体内植入物序贯治疗优于地塞米松单药治疗。
Br J Ophthalmol. 2015 Feb;99(2):210-4. doi: 10.1136/bjophthalmol-2014-305661. Epub 2014 Aug 19.
4
A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion.地塞米松玻璃体内植入物与雷珠单抗治疗视网膜分支静脉阻塞的12个月多中心平行组比较
Eur J Ophthalmol. 2018 Nov;28(6):697-705. doi: 10.1177/1120672117750058. Epub 2018 Apr 9.
5
Early results of dexamethasone implant, ranibizumab, and triamcinolone in macular edema due to branch retinal vein occlusion.地塞米松植入物、雷珠单抗和曲安奈德治疗视网膜分支静脉阻塞所致黄斑水肿的早期结果
Eur J Ophthalmol. 2016 Jan-Feb;26(1):54-9. doi: 10.5301/ejo.5000637. Epub 2015 Jun 11.
6
Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.玻璃体内注射贝伐单抗后再行地塞米松植入与地塞米松植入单药治疗视网膜静脉阻塞伴黄斑水肿的比较。
Ophthalmologica. 2012;228(2):110-6. doi: 10.1159/000338732. Epub 2012 Jun 23.
7
Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA.美国雷珠单抗玻璃体内注射和地塞米松玻璃体内植入治疗视网膜静脉阻塞的治疗模式
Eye (Lond). 2017 Apr;31(4):551-559. doi: 10.1038/eye.2016.269. Epub 2016 Dec 2.
8
Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience.重复玻璃体内注射地塞米松治疗视网膜静脉阻塞继发的黄斑囊样水肿（无论是否转换为抗血管内皮生长因子药物）的安全性和长期疗效：一项为期3年的经验
Graefes Arch Clin Exp Ophthalmol. 2018 Aug;256(8):1441-1448. doi: 10.1007/s00417-018-4016-7. Epub 2018 May 31.
9
RETINA.
Retina. 2018 Jun;38 Suppl 3:1-13.
10
THE OMAR STUDY: Comparison of Ozurdex and Triamcinolone Acetonide for Refractory Cystoid Macular Edema in Retinal Vein Occlusion.奥马尔研究：玻璃体内注射曲安奈德与地塞米松玻璃体内植入剂治疗视网膜静脉阻塞性难治性黄斑囊样水肿的对比研究
Retina. 2015 Jul;35(7):1393-400. doi: 10.1097/IAE.0000000000000475.

引用本文的文献

1
Complement C3 is downregulated following ranibizumab intervention in experimental central retinal vein occlusion.在实验性视网膜中央静脉阻塞中，雷珠单抗干预后补体 C3 下调。
Mol Vis. 2024 Jul 2;30:268-277. eCollection 2024.
2
Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion.贝伐单抗干预实验性视网膜中央静脉阻塞的蛋白质组学分析
J Pers Med. 2023 Nov 7;13(11):1580. doi: 10.3390/jpm13111580.
3
Dexamethasone Intravitreal Implant Is Active at the Molecular Level Eight Weeks after Implantation in Experimental Central Retinal Vein Occlusion.
地塞米松玻璃体内植入物在实验性视网膜中央静脉阻塞植入 8 周后在分子水平上具有活性。
Molecules. 2022 Sep 3;27(17):5687. doi: 10.3390/molecules27175687.